48 - Ten-Year Outcomes of Endoscopic Sleeve Gastroplasty for the Treatment of Obesity

Ali Lahooti, BS¹, Anam Rizvi, MD¹, Muhammad Usman. Baig, MBBS¹, Cynthia Akagbosu, MD, MA¹, SriHari Mahadev, MD², Kartik Sampath, MD¹, David L. Carr-Locke, MA, MD, FACG¹, Louis Aronne, MD¹, Alpana Shukla, MD¹, Kate E. Johnson, BS¹, Andrea Herr, NP¹, Carolyn Newberry, MD², Sonal Kumar, MD, MPH³, Reem Sharaiha, MD^1
1Weill Cornell Medicine, New York, NY; ²New York-Presbyterian / Weill Cornell Medical Center, New York, NY; ³Weill Cornell Medical College, New York, NY

Introduction: Obesity represents a pervasive and escalating global health pandemic, and despite its prominence, there is a notable absence of data illustrating the long-term effectiveness of endoscopic sleeve gastroplasty (ESG) as a novel solution. This study assesses the long-term efficacy, safety, and durability of ESG for treatment of obesity 10 years post-procedure.

Methods: Prospectively collected data was obtained from patients with obesity who underwent ESG between August 2013 and May 2024 at a single large tertiary hospital. Patients were eligible if they had a body mass index of >30 kg/m2 (or >27 with comorbidities). ESG was performed by a single therapeutic endoscopist utilizing a full-thickness endoscopic suturing device. Anthropometric measurements and laboratory assessments were conducted at the initial evaluation prior to the procedure, as well as during regular follow-up appointments post-procedure. Patients were followed for up to 10 years after their procedure. The primary outcome was weight loss at 10 years after the procedure reported as percent total body weight loss (%TBWL). The safety and durability of ESG were determined through rates of adverse events and need for multiple procedures, respectively.

Results: 404 patients (76.2% female), (39% white) with a mean age of 45 ±11.9 years, and mean BMI of 37.2±5.8kg/m2 (27.1-64) underwent ESG (Table 1). Out of 404 patients, 397, 335, 249, and 110 patients were eligible for 1-, 3-, 5-, and 10- year follow up, with complete follow-up rates of 84.6%, 66.3%, 78.7%, and 61.8% respectively. At 10 years, mean TBWL was 15.8% (95% CI, 12.2-19.5, p < .001) and 83% and 70% of patients maintained 5 and 10 %TBWL, respectively (Figure 1). At 10 years, 44, 10.9% had endoscopic revision via retightening or resuturing. There was an overall rate of 3 (0.01%) moderate adverse events (AEs), without any severe or fatal AEs

Discussion: Our results suggest that ESG is effective and safe for treatment of obesity, with durable long- term results for at least up to 10 years after the procedure. This procedure should be considered as a dependable option for treatment of obesity particularly among individuals who have not attained their desired results through lifestyle modifications and those who are not eligible for or choose not to undergo bariatric surgery.




Disclosures:


Ali Lahooti, BS¹, Anam Rizvi, MD¹, Muhammad Usman. Baig, MBBS¹, Cynthia Akagbosu, MD, MA¹, SriHari Mahadev, MD², Kartik Sampath, MD¹, David L. Carr-Locke, MA, MD, FACG¹, Louis Aronne, MD¹, Alpana Shukla, MD¹, Kate E. Johnson, BS¹, Andrea Herr, NP¹, Carolyn Newberry, MD², Sonal Kumar, MD, MPH³, Reem Sharaiha, MD¹, 48, Ten-Year Outcomes of Endoscopic Sleeve Gastroplasty for the Treatment of Obesity, ACG 2024 Annual Scientific Meeting Abstracts. Philadelphia, PA: American College of Gastroenterology.